Figure 3:

Examples of 2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL)–avid lesions with benign pathologic findings at biopsy. Red arrows highlight the lesions with benign biopsy results. (A–D) DCFPyL maximum intensity projection image (A), axial CT scan (B), axial fused DCFPyL PET/CT scan (C), and CT scan obtained during image-guided biopsy (D) of a DCFPyL-avid (standardized uptake value, 6.9) right second rib sclerosis in a 68-year-old man with prostate cancer after prostatectomy and salvage radiation. Prostate-specific antigen (PSA) level was 1.0 ng/mL. (E–H) DCFPyL maximum intensity projection image (E), axial CT scan (F), axial fused DCFPyL PET/CT scan (G), and CT scan obtained during image-guided biopsy (H) of DCFPyL-avid (standardized uptake value, 12.7) left inferior pubic ramus sclerosis in a 59-year-old man with newly diagnosed prostate cancer (Gleason score, 8; PSA level, 19.7 ng/mL). (I–L) DCFPyL maximum intensity projection image (I), axial CT scan (J), axial fused DCFPyL PET/CT scan (K), and CT scan obtained during image-guided biopsy (L) of a DCFPyL-avid (standardized uptake value, 4.7) subcentimeter right external iliac node in a 61-year-old man with prostate cancer after prostatectomy. PSA level was 0.4 ng/mL. In each of these men, the biopsy results were benign.